Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial
West Family Memorial Fund, Inagene and Timeposters Fellowship and industry funding for speaker/consultation/research fees from iGan, Boehringer Ingelheim, Abbvie, Braxia Health (Canadian Rapid Treatment Centre of Excellence), Braxia Scientific, Janssen, Allergan, Lundbeck, Sunovion and COMPASS
Some of our most exciting research at Encore Research Group is for these new cholesterol lowering medications such as PCSK9 inhibitors
Claims about human muscle growth or performance are not supported by clinical evidence
US$ 26.44
US$ 26.09
US$ 20.32
US$ 27.15
US$ 26.95
